Tofacitinib citrate / Tofacitinib is one of the first orally available Janus family kinases inhibitors (JAKis) (L04AF) with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, JAK1, respectively

What effect does Tofacitinib have on intestinal mucosal macrophages when used against inflammatory bowel disease?

Tofacitinib downregulated M1-type macrophage proportion and promoted M2 polarization with upregulating CD206, CD163, and [Interleukin-10 (IL-10)](brain://7rbnFozGlk…

References (Sources)

A JAK1 selective kinase inhibitor and Tofacitinib affect macrophage activation and function
De Vries et al. 2019 Inflamm Bowel Dis 25(4): 647-660

AI Chat

11/5/2026

Chat with our artificial intelligence:

Start chat!

Tofacitinib (L04AF01)

Welcome to meRfi Microbiome!

Navigation

Contents

What is Tofacitinib?

What effect does Tofacitinib have on intestinal mucosal macrophages when used against inflammatory bowel disease?

References (Sources)

AI Chat

Links